Cost Effectiveness of Combined Contingency Management and Cognitive Behavioral Therapy for Alcohol Use Disorder

Sponsor
Duke University (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT03987581
Collaborator
(none)
140
1
4
48.2
2.9

Study Details

Study Description

Brief Summary

Alcohol contributes to 88,000 deaths and costs an estimated $223 billion annually in the United States. Alcohol use disorder (AUD) is highly prevalent in veterans. The positive public health impact of reducing heavy drinking among veterans with AUD would prevent significant medical morbidity and mortality. Contingency management (CM) is an intensive behavioral therapy that provides incentives to individuals for reducing substance use. Monitoring alcohol abstinence usually requires daily monitoring. Because of this difficulty, CM approaches for treatment of AUD are not currently available to people with AUD. Our group has developed a mobile smart-phone application that allows patients to video themselves using an alcohol breath monitor and transmit the encrypted data to a secure server. This innovation has made the use of CM for outpatient AUD treatment feasible. The aim of the current study is to evaluate the effectiveness and cost effectiveness of CM as an add-on to cognitive behavioral therapy for AUD. The trial will also explore the potential usefulness of a long-term abstinence incentive ontreatment utilization and alcohol outcomes. Proposed is a trial in which 140 veterans with AUD will be randomized to receive either CM as an add-on to evidence-based CBT or CBT alone. Veterans will also be randomized to one of two long-term incentive conditions (i.e., receipt of a monetary incentive for abstinence/low-risk drinking at 6- months vs. no incentive). This project aims to advance AUD treatment by 1) testing the effectiveness of a mobile health approach that makes CM for AUD feasible, and 2) providing highly needed cost-effectiveness data on the use of behavioral incentives as an adjunct to CBT for the treatment of AUD. These aims are designed to address two significant barriers to the implementation of CM for AUD.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Cognitive Behavioral Therapy (CBT)
  • Behavioral: Mobile Contingency Management (mCM)
  • Behavioral: Long-term incentive
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
140 participants
Allocation:
Randomized
Intervention Model:
Factorial Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Cost Effectiveness of Combined Contingency Management and Cognitive Behavioral Therapy for Alcohol Use Disorder
Actual Study Start Date :
Nov 26, 2019
Anticipated Primary Completion Date :
May 31, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: CBT + mCM + incentive

Participants in this arm will receive 12 sessions of cognitive behavioral treatment, mobile contingency management for alcohol abstinence, and a monetary incentive for 30-day abstinence at the 6-month follow-up.

Behavioral: Cognitive Behavioral Therapy (CBT)
Twelve in-person counseling sessions designed to assist participants with becoming abstinent from alcohol use (or reduce use).
Other Names:
  • CBT
  • Behavioral: Mobile Contingency Management (mCM)
    Abstinence (measured by breath alcohol) will be intermittently reinforced. For each breath alcohol concentration reading that tests negative, a participant will earn a virtual scratch-off lottery ticket that contains 100 different values.
    Other Names:
  • mCM
  • CM
  • Behavioral: Long-term incentive
    This incentive is $300 for self-reported and bioverified 30-day abstinence from heavy drinking at the follow-up scheduled for 6-months after the initial quit date
    Other Names:
  • Incentive
  • Experimental: CBT + mCM + no incentive

    Participants in this arm will receive 12 sessions of cognitive behavioral treatment and mobile contingency management for alcohol abstinence. They will not receive monetary incentive for 30-day abstinence at the 6-month follow-up.

    Behavioral: Cognitive Behavioral Therapy (CBT)
    Twelve in-person counseling sessions designed to assist participants with becoming abstinent from alcohol use (or reduce use).
    Other Names:
  • CBT
  • Behavioral: Mobile Contingency Management (mCM)
    Abstinence (measured by breath alcohol) will be intermittently reinforced. For each breath alcohol concentration reading that tests negative, a participant will earn a virtual scratch-off lottery ticket that contains 100 different values.
    Other Names:
  • mCM
  • CM
  • Experimental: CBT alone + incentive

    Participants in this arm will receive 12 sessions of cognitive behavioral treatment and a monetary incentive for 30-day abstinence at the 6-month follow-up. They will not receive contingency management for alcohol abstinence during the treatment period.

    Behavioral: Cognitive Behavioral Therapy (CBT)
    Twelve in-person counseling sessions designed to assist participants with becoming abstinent from alcohol use (or reduce use).
    Other Names:
  • CBT
  • Behavioral: Long-term incentive
    This incentive is $300 for self-reported and bioverified 30-day abstinence from heavy drinking at the follow-up scheduled for 6-months after the initial quit date
    Other Names:
  • Incentive
  • Active Comparator: CBT alone + no incentive

    Participants in this arm will receive 12 sessions of cognitive behavioral treatment. They will not receive monetary incentive for 30-day abstinence at the 6-month follow-up. They will not receive contingency management for alcohol abstinence during the treatment period.

    Behavioral: Cognitive Behavioral Therapy (CBT)
    Twelve in-person counseling sessions designed to assist participants with becoming abstinent from alcohol use (or reduce use).
    Other Names:
  • CBT
  • Outcome Measures

    Primary Outcome Measures

    1. Average number of heavy drinking days [6-month post quit visit]

      At the 6-month follow-up visit, participants will self-report the number of heavy drinking (> 5 drinks in day for men, > 4 drinks in a day for women) days they have had in the past thirty days.

    Secondary Outcome Measures

    1. Average number of heavy drinking days [12-month post quit visit]

      At the 12-month follow-up visit, participants will self-report the number of heavy drinking (> 5 drinks in day for men, > 4 drinks in a day for women) days in the past thirty days.

    2. Average number of binge drinking days [6-month post quit visit]

      Participants will self-report the number of binge drinking (heavy drinking within a 2-hour period) days in the past thirty days.

    3. Average number of binge drinking days [12-month post quit visit]

      Participants will self-report the number of binge drinking (heavy drinking within a 2-hour period) days in the past thirty days.

    4. Average number of drinking days [6-month post quit visit]

      Participants will self-report the number of drinking days in the past thirty days.

    5. Average number of drinking days [12-month post quit visit]

      Participants will self-report the number of drinking days in the past thirty days.

    6. Average number of drinks per drinking day [6-month post quit visit]

      Participants will self-report the number of drinks on drinking days in the past 30 days.

    7. Average number of drinks per drinking day [12-month post quit visit]

      Participants will self-report the number of drinks on drinking days in the past 30 days.

    8. Self-reported abstinence [6-month post quit visit]

      Participants will self-report whether or not consumed any alcohol in the past 30 days.

    9. Self-reported abstinence [12-month post quit visit]

      Participants will self-report whether or not consumed any alcohol in the past 30 days.

    10. Bioverification of low-risk drinking [Post-treatment, approximately 14 weeks]

      Participants will provide a fingerstick blood sample. Phosphatidylethanol (PEth) testing will provide any evidence of excessive alcohol use in previous 4 weeks.

    11. Bioverification of low-risk drinking [6-month post quit visit]

      Participants will provide a fingerstick blood sample. Phosphatidylethanol (PEth) testing will provide any evidence of excessive alcohol use in previous 4 weeks.

    12. Bioverification of low-risk drinking [12-month post quit visit]

      Participants will provide a fingerstick blood sample. Phosphatidylethanol (PEth) testing will provide any evidence of excessive alcohol use in previous 4 weeks.

    13. Treatment utilization [6-month post quit visit]

      Participants will provide self-report on use of adjunct treatments (e.g., Alcoholics Anonymous, group counseling) for alcohol use during the period between post-treatment and follow-ups. Where available, Department of Veterans Affairs administrative data will be used to determine enrollment or involvement in aftercare treatment.

    14. Treatment utilization [12-month post quit visit]

      Participants will provide self-report on use of adjunct treatments (e.g., Alcoholics Anonymous, group counseling) for alcohol use during the period between post-treatment and follow-ups. Where available, Department of Veterans Affairs administrative data will be used to determine enrollment or involvement in aftercare treatment.

    15. Health care related quality of life [12-month post quit visit]

      Health care related quality of life will be measured by the EuroQol.

    16. CBT treatment engagement [Post-treatment, approximately 14 weeks]

      The number of cognitive behavioral therapy treatment sessions completed by each participant will be measured to determine treatment engagement

    17. Incremental Cost-Effectiveness Ratio [12-month post quit visit]

      Measure of cost-effectiveness; costs as the numerator and effectiveness as measured by quality-adjusted life years (QALY) as the denominator

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • are an enrolled veteran at the DVAHCS for primary care,

    • have current AUD (meeting past month DSM-5 criteria), and

    • are willing to make a quit attempt and/or reduce alcohol use to low risk levels.

    Exclusion Criteria:
    • have fewer than 3 days of abstinence,

    • have a history of clinically significant alcohol withdrawal, as indicated by a score of 10 or more on the Clinical Institute Withdrawal Assessment of Alcohol (CIWA), or

    • are currently receiving professional behavioral treatment for AUD.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Duke University Medical Center Durham North Carolina United States 27706

    Sponsors and Collaborators

    • Duke University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Duke University
    ClinicalTrials.gov Identifier:
    NCT03987581
    Other Study ID Numbers:
    • PRO00101744
    First Posted:
    Jun 17, 2019
    Last Update Posted:
    Apr 1, 2022
    Last Verified:
    Mar 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 1, 2022